Tulmimetostat (also known as CPI-0209 or DZR123) is an orally available, investigational antineoplastic drug being developed for the treatment of various advanced solid tumors and lymphomas that is being developed by MorphoSys.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.